SAN DIEGO, Nov. 10, 2011 /PRNewswire/ -- Synteract, Inc., a full-service, global contract research organization (CRO), and MediciNova, Inc., a publicly traded biopharmaceutical company focused on novel, small-molecule therapeutics for the treatment of serious diseases, will team up to support the American Lung Association (ALA) in California in their annual Fight For Air Walk through team participation and donations. The two companies also are working together on a Phase 2 trial studying MediciNova's compound MN-221 to combat asthma and chronic obstructive pulmonary disease (COPD).
The American Lung Association Fight For Air Walk is a statewide event held at venues throughout California to increase awareness and raise funds for the Lung Association's fight for clean air and healthy lungs. Synteract and MediciNova will each field walking teams on Sunday, Nov. 13th at Embarcadero Park South in San Diego in recognition of Lung Cancer Awareness Month and COPD Awareness Month, both in November. Synteract exceeded its original team fundraising goal and has already doubled the amount. The company-wide initiative includes bake sales and other activities that support fundraising. The three-mile walk will bring co-workers, friends and families together in support of the work of the American Lung Association in California.
"Synteract and MediciNova are pleased to be able to help the American Lung Association in its fundraising efforts and education of the community about such debilitating diseases as asthma and COPD," said Ali Sadighian, vice president, business development at Synteract. "With the support of our team walkers, we are participating in ALA's efforts to save lives today and keep America healthy tomorrow."
MediciNova, Inc. acquires and develops novel, small-molecule therapeutics for the treatment of serious diseases with a commercial focus on the U.S. market. MediciNova's lead drug candidate, MN-221, is an intravenous treatment for patients suffering from acute exacerbations of asthma and COPD. Currently MediciNova's MN-221, a highly selective beta(2)-adrenergic receptor agonist, is in a Phase 2 clinical trial for acute exacerbations of asthma. The study, being conducted with Synteract, continues to enroll patients through December, involves 15 sites across the U.S. and 200 patients.
Those who are interested in participating in the walk or donating to the association can contact Synteract representative Joanna Dojillo at 760-268-8296 or the American Lung Association in California at www.lungusa.org/california.
About Synteract, Inc.
Synteract is a privately-held, full-service contract research organization, serving clinical trial needs of biotechnology, medical device, and pharmaceutical companies. Synteract provides high quality, customized service, working closely with drug and device sponsors. Headquartered in California, with offices in North Carolina and Czech Republic, Synteract offers clinical expertise in multiple therapeutic areas, including a strong emphasis in oncology, central nervous system (CNS), cardiovascular, respiratory, and ophthalmology. Information: http://www.synteract.com; (760) 268.8200.
About MediciNova, Inc.
MediciNova, Inc. is a publicly traded biopharmaceutical company acquiring and developing novel, small-molecule therapeutics for the treatment of serious diseases with a commercial focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential, and patent coverage of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds to be monetized. For more information, visit www.medicinova.com
Clearpoint Agency, for Synteract
SOURCE Synteract, Inc.